[A blue text on a black background
AI-generated content may be incorrect.]
4basebio PLC
("4basebio" or the "Company")
Grant of Options
Director/PDMR Dealing
Cambridge, UK - 22 July 2026-4basebio PLC (AIM: 4BB), a company pioneering an
enzymatically-produced DNA technology serving the next generation genetic
medicines markets, announces that it has granted in aggregate 684,872 options
over ordinary shares of the Company, (the "Share Options") to certain Directors
and a PDMR of the Company.
634,872 of the Share Options granted to Dr. Amy Walker, Dr. Manja Boerman and
Dr. Heikki Lanckriet have an exercise price of £5.05 per ordinary share
(breakdown below), being the closing mid-market price on 1 May 2026, and the
remaining 50,000 Share Options granted to Richard Bungay have an exercise price
of £5.25 per ordinary share, being the closing mid-market price on 21 July 2026.
Further details are set out in the Notification of Dealing Form below.
Number of Share Resultant Number of As a % of Current
Options Granted Share Options Held Issued Share
Capital
Dr. Amy 387,872 430,000 2.77%
Walker
Dr. Manja 172,000 172,000 1.11%
Boerman
Dr. Heikki 75,000 101,137 0.65%
Lanckriet
Richard 50,000 50,000 0.32%
Bungay
Total 684,872 753,127 4.85%
Certain amounts of the Share Options have been granted to Dr. Amy Walker and Dr.
Manja Boerman pursuant to delayed option grants that were agreed in 2024 and
2025.
301,872 of the Share Options granted to Dr. Amy Walker and all of the Share
Options granted to Dr. Manja Boerman vest annually in equal tranches over four
years from 1 May 2026. 86,000 of the Share Options granted to Dr. Amy Walker
will become exercisable if the volume-weighted average share price of the
Company exceeds £15.00 for 30 consecutive trading days. The Share Options
granted to Richard Bungay vest annually in equal tranches over four years from
21 July 2026. The Share Options granted to Dr. Heikki Lanckriet vest in full
immediately on grant.
The issued share capital of the Company is 15,538,518 ordinary shares. Following
the grant of the Share Options, the Company will have 1,354,024 options over
ordinary shares in issue representing approximately 8.71 per cent. of the
Company's current issued share capital
This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse
(Amendment) (EU Exit) Regulations 2019/310.
For further enquiries, please contact:
4basebio PLC
Dr. Amy Walker, CEO
+44 (0)12 2396 7943
Cairn Financial Advisers LLP (Nominated Adviser)
Jo Turner / Sandy Jamieson / Ed Downes
+44 (0)20 7213 0880
Cavendish Capital Markets Limited (Joint Broker)
Geoff Nash / Nigel Birks
+44 (0)20 7220 0500
RBC Capital Markets (Joint Broker)
Kathryn Deegan / Matthew Coakes
+44 (0)20 7653 4000
ICR Healthcare (Media and Investor Relations)
Mary-Jane Elliott / Jessica Hodgson
+44 (0)203 707 5700
About 4basebio
4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the
use of synthetic DNA to enable next-generation therapeutics and vaccines.
Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP
-grade synthetic DNA and mRNA with superior speed, purity, and scalability,
overcoming the limitations of plasmid-based systems. The company offers
application-specific DNA constructs tailored to the diverse needs of gene
therapies, genome editing, mRNA production, and DNA vaccines, helping partners
accelerate proof-of-concept studies and reach clinical milestones more
efficiently while maintaining the highest standards of safety and quality.
For more information, visit 4basebio.com (https://www.4basebio.com/).
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
+--+----------------+----------------------------------------------------------+
|1 |Details of the |
| |persons |
| |discharging |
| |managerial |
| |responsibilities |
| |/ person closely |
| |associated |
+--+----------------+----------------------------------------------------------+
|a)|Name |1) Dr. Amy Walker |
| | | |
| | |2) Dr. Manja Boerman |
| | | |
| | |3) Dr. Heikki Lanckriet |
| | | |
| | |4) Richard Bungay |
+--+----------------+----------------------------------------------------------+
|2 |Reason for the |
| |notification |
+--+----------------+----------------------------------------------------------+
|a)|Position/Status |1) Chief Executive Officer |
| | | |
| | |2) Executive Chair |
| | | |
| | |3) Non-executive Director |
| | | |
| | |4) PDMR |
+--+----------------+----------------------------------------------------------+
|b)|Initial |Initial notification |
| |notification/ | |
| |Amendment | |
+--+----------------+----------------------------------------------------------+
|3 |Details of the |
| |issuer, emission |
| |allowance market |
| |participant, |
| |auction |
| |platform, |
| |auctioneer or |
| |auction monitor |
+--+----------------+----------------------------------------------------------+
|a)|Name |4basebio plc |
+--+----------------+----------------------------------------------------------+
|b)|LEI |213800E2DX9EAIUNCB30 |
+--+----------------+----------------------------------------------------------+
|4 |Details of the |
| |transaction(s): |
| |section to be |
| |repeated for (i) |
| |each type of |
| |instrument; (ii) |
| |each type of |
| |transaction; |
| |(iii) each date; |
| |and (iv) each |
| |place where |
| |transactions |
| |have been |
| |conducted |
+--+----------------+----------------------------------------------------------+
|a)|Description of |Options over Ordinary Shares |
| |the financial | |
| | |ISIN: GB00BMCLYF79 |
| |instrument, type| |
| |of | |
| | | |
| |instrument | |
| | | |
| |Identification | |
| |code | |
+--+----------------+----------------------------------------------------------+
|b)|Nature of the |Grant of Options over Ordinary Shares |
| |transaction | |
+--+----------------+----------------------------------------------------------+
|c)|Price(s) and | |
| |volume(s) |+---------------------------+-----------------------------|
| | |-+ |
| | ||Price(s) per share (p) |Volume(s) |
| | || |
| | |+---------------------------+-----------------------------|
| | |-+ |
| | ||i) 505p|i) |
| | |387,872| |
| | || | |
| | || |
| | ||ii) 505p |ii) 172,000|
| | || |
| | || | |
| | || |
| | ||iii) 505p |iii) 75,000 |
| | || |
| | || | |
| | || |
| | ||iv) 525p |iv) 50,000 |
| | || |
| | |+---------------------------+-----------------------------|
| | |-+ |
+--+----------------+----------------------------------------------------------+
|d)|Aggregated |See above |
| |information | |
| | | |
| |-Aggregated | |
| |volume | |
| | | |
| |-Aggregated | |
| |Price | |
+--+----------------+----------------------------------------------------------+
|e)|Date of |21 July 2026 |
| |transaction | |
+--+----------------+----------------------------------------------------------+
|f)|Place of |Outside a trading venue |
| |transaction | |
+--+----------------+----------------------------------------------------------+
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Public/22442/4376666/bc6303159b63f792_org.png 4376666_0.png
